Advanced search
Publication Cover
Leukemia & Lymphoma Volume 36, 2000 - Issue 5-6
Submit an article Journal homepage
127
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia

Jorge Cortes Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USACorrespondence[email protected]
,
Elihu Estey Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Miloslav Beran Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Susan O'brien Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Francis Giles Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Charles Roller Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Michael Keating Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
&
Hagop Kantarjian Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
 show all
Pages 479-484 | Received 28 Jul 1999, Published online: 01 Jul 2009

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Francis J. Giles$suffix/text()$suffix/text(). (2007) Bendamustine and cloretazine: Alkylators with sharply contrasting activity in AML. Leukemia & Lymphoma 48:6, pages 1064-1066.
Read now
Slobodan Stanisic & Matt Kalaycio. (2002) Treatment of refractory and relapsed acute myelogenous leukemia. Expert Review of Anticancer Therapy 2:3, pages 287-295.
Read now
Banu Arun & Eugene P Frenkel. (2001) Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opinion on Pharmacotherapy 2:3, pages 491-505.
Read now

Articles from other publishers (26)

Timothy Kubal & Jeffrey E. Lancet. (2013) The thorny issue of relapsed acute myeloid leukemia. Current Opinion in Hematology 20:2, pages 100-106.
Crossref
Mark R. Litzow, Megan Othus, Larry D. Cripe, Steven D. Gore, Hillard M. Lazarus, Sandra J. Lee, John M. Bennett, Elisabeth M. Paietta, Gordon W. Dewald, Jacob M. Rowe & Martin S. Tallman. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. British Journal of Haematology 148:2, pages 217-225.
Crossref
Tadeusz Robak & Agnieszka Wierzbowska. (2009) Current and emerging therapies for acute myeloid leukemia. Clinical Therapeutics 31, pages 2349-2370.
Crossref
Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta, Ewa Wawrzyniak, Barbara Cebula, Jerzy Hołowiecki, Sławomira Kyrcz-Krzemień, Sebastian Grosicki, Sebastian Giebel, Aleksander B. Skotnicki, Beata Piątkowska-Jakubas, Kazimierz Kuliczkowski, Marek Kiełbiński, Krystyna Zawilska, Janusz Kłoczko & Agata Wrzesień-Kuś. (2007) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem. European Journal of Haematology 80:2, pages 115-126.
Crossref
Ahmed Aribi, Carlos Bueso‐Ramos, Eli Estey, Zeev Estrov, Susan O'Brien, Francis Giles, Stefan Faderl, Deborah Thomas, Partow Kebriaei, Guillermo Garcia‐Manero, Sherry Pierce, Jorge Cortes, Hagop Kantarjian & Farhad Ravandi. (2007) Biphenotypic acute leukaemia: a case series. British Journal of Haematology 138:2, pages 213-216.
Crossref
Francis GilesDavid RizzieriJudith KarpNorbert VeyFarhad RavandiStefan FaderlKhuda Dad KhanGregor VerhoefPierre WijermansAnjali AdvaniGail RobozHagop KantarjianSyed Fazl Ali BilgramiAugustin FerrantSimon M.G.J. DaenenVerena KarstenAnn CahillMaher AlbitarGhulam MuftiSusan O'Brien. (2007) Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia. Journal of Clinical Oncology 25:1, pages 25-31.
Crossref
Ursula Creutzig. 2010. Childhood Leukemias. Childhood Leukemias 540 547 .
Hans Minderman, Kieran L. O’Loughlin, Patrick F. Smith, Lakshmi Pendyala, William R. Greco, Kimberly G. Sweeney, Laurie A. Ford, Meir Wetzler & Maria R. Baer. (2005) Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 57:1, pages 73-83.
Crossref
Jonathan E. Kolitz. 2006. Oncology. Oncology 1160 1181 .
Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol & Hagop Kantarjian. (2005) Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia. Clinical Cancer Research 11:21, pages 7817-7824.
Crossref
A. Wrzesień-Kuś, T. Robak, A. Wierzbowska, E. Lech-Marańda, A. Pluta, E. Wawrzyniak, A. Krawczyńska, K. Kuliczkowski, G. Mazur, M. Kiebiński, A. Dmoszyńska, M. Wach, A. Hellmann, W. Baran, J. Hołowiecki, S. Kyrcz-Krzemień & S. Grosicki. (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology 84:9, pages 557-564.
Crossref
Javier Bolaños-Meade, Chuanfa Guo, Ivana Gojo & Judith E Karp. (2004) A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leukemia Research 28:6, pages 571-577.
Crossref
Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol & Hagop Kantarjian. (2004) A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia. Clinical Cancer Research 10:9, pages 2908-2917.
Crossref
Francis J. Giles, Martin S. Tallman, Guillermo Garcia-Manero, Jorge E. Cortes, Deborah A. Thomas, William G. Wierda, Srdan Verstovsek, Marta Hamilton, Emma Barrett, Maher Albitar & Hagop M. Kantarjian. (2004) Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100:7, pages 1449-1458.
Crossref
Mark R Litzow. (2004) The therapy of relapsed acute leukaemia in adults. Blood Reviews 18:1, pages 39-63.
Crossref
Blake Tomkinson, Ray Bendele, Francis J. Giles, Eric Brown, Atherton Gray, Karen Hart, Jeremy D. LeRay, Denny Meyer, Michelle Pelanne & David L. Emerson. (2003) OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leukemia Research 27:11, pages 1039-1050.
Crossref
E A Kolb & P G Steinherz. (2003) A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 17:10, pages 1967-1972.
Crossref
A. Wrzesień-Kuś, T. Robak, E. Lech-Marańda, A. Wierzbowska, A. Dmoszyńska, M. Kowal, J. Hołowiecki, S. Kyrcz-Krzemień, S. Grosicki, S. Maj, A. Hellmann, A. Skotnicki, W. Je˛drzejczak & K. Kuliczkowski. (2003) A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). European Journal of Haematology 71:3, pages 155-162.
Crossref
Sami N Malek & Steven D Gore. (2003) Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?. Leukemia Research 27:1, pages 1-3.
Crossref
Xavier Thomas. (2002) Nouvelles approches thérapeutiques des leucémies aiguës de l'adulte. Revue Française des Laboratoires 2002:344, pages 55-65.
Crossref
Seung Tae Lee, Joon Ho Jang, Hyung Chan Suh, Jee Sook Hahn, Yun Woong Ko & Yoo Hong Min. (2001) Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high‐risk myelodysplastic syndrome. American Journal of Hematology 68:4, pages 237-245.
Crossref
RA Larson. (2001) New agents for induction and postremission therapy of acute myeloid leukemia. Leukemia 15:4, pages 675-676.
Crossref
Francis Giles, Jorge Cortes, Guillermo Garcia-Manero, Stephen Kornblau, Elihu Estey, Monica Kwari, Anthony Murgo & Hagop Kantarjian. (2001) Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia. Investigational New Drugs 19:1, pages 13-20.
Crossref
MILOSLAV BERAN & HAGOP M. KANTARJIAN. (2006) Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treatment of Hematologic Malignancies. Annals of the New York Academy of Sciences 922:1, pages 247-259.
Crossref
. (2000) Current Awareness. Hematological Oncology 18:2, pages 77-84.
Crossref
Jorge Cortes & Hagop M. Kantarjian. (2000) Promising Approaches in Acute Leukemia. Investigational New Drugs 18:1, pages 57-82.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.